Get a glimpse into our company and investor data—powered by the PitchBook Platform
Developer of vivo oncology efficacy and toxicity assays designed to optimise pre-clinical and discovery studies. The company's technology finds the best anticancer candidate treatment by detecting the first in vivo toxicity effects of candidate compounds, enabling healthcare providers to accelerate the overall drug discovery process to answer unmet medical needs in oncology.
You’re viewing a free company profile from the PitchBook Platform. To explore Inovotion’s full profile, request a free trial.
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
3. Grant | 17-Oct-2016 | $55.2K | Completed | Generating Revenue | ||
2. Accelerator/Incubator | Completed | Generating Revenue | ||||
1. Angel (individual) | Completed | Generating Revenue |
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Board Seat |
Contact Info |
---|---|---|---|---|---|---|
Horizon 2020 | Government | 000 0000 | 000000 0 | |||
Angelor Capitale | Angel Group | Minority | 000 0000 | 000000 0 | ||
North Shore InnoVentures | Accelerator/Incubator | Minority | 000 0000 | 000000 0 |